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Rationale and objective 
Early diagnosis of cancer is imperative to reduce the cancer burden in the UK and improve cancer 
survival. Identifying early markers of cancer can help general practitioners to direct patients at the 
greatest risk of cancer to appropriate investigative services. A raised platelet count, or 
thrombocytosis, has been linked to malignancy1 2 and identified as a marker of poor prognosis in 
secondary care3-9, but there is little evidence around the importance of this marker in a primary care 
setting, within a diagnostic context. This review aims to identify and explore the body of evidence 
concerning the association between thrombocytosis and cancer in primary care. This protocol was 
produced using guidance from the PRISMA-P statement.10 
Research questions 
 Are adults aged over 40 with thrombocytosis at greater risk of cancer than those with normal 
platelet counts? 
 Which cancer sites have been found to be associated with thrombocytosis in primary care, and 
which are not? 
Inclusion criteria 
 Any type of cancer or cancer site 
 Studies that have investigated the association between cancer and platelets (using platelets as a 
diagnostic tool, not prognostic factor). 
 Studies based in primary care. 
 Includes adults >40y 
 English language 
 Any observational, cohort, case-control study or literature or systematic review (due to the 
nature of the research question, RCTs were excluded) 
 The last 30 years 
 
Exclusion criteria: 
 Studies that have investigated thrombocytosis or platelet count as a prognostic tool or guide to 
therapy.  
 Case studies and RCTs 
o Case studies are excluded as this review is interested in population-level or cohort based 
studies that can provide evidence on a large number of patients.  
o RCTs are excluded as the independent variable in this study cannot be randomised.  
 
Search strategy 
The search strategy will comprise the following elements to identify relevant papers: 
 Searching of electronic bibliographies including: 
o EMBASE (OvidSP) 1996-2014 (week29) 
o Medline (OVIDpalt) 
o Web of Science 
o The Cochrane Library 
 
 Scrutiny of reference lists of included studies 
 Contact with experts in the field 
Study selection criteria and procedures  
References will be uploaded to reference management software (Endnote X5). Duplicates will be 
checked and removed. The abstracts and titles of references retrieved by the electronic searches will 
be screened for relevance by SB using the pre-defined inclusion and exclusion criteria. Hits will be 
double screened by ES. Any differences in opinion over paper to include or exclude will be resolved 
by discussion.  
Full text copies of potentially relevant studies that appear to meet all inclusion criteria will be 
obtained.  The retrieved articles will be assessed for inclusion by checking each article against the 
pre-specified inclusion and exclusion criteria. A flow chart will be produced which will outline the 
study selection process, and reasons for exclusion of full text papers will be detailed.   
Quality assessment and data extraction strategy 
Study quality will be assessed using QUADAS-2. Data will be extracted into custom made data 
extraction forms by SB and WH. Data concerning the number of patients with and without cancer 
who had pre-diagnosis thrombocytosis will be the main extracted values. 
Evidence synthesis 
The evidence will be presented and synthesised as appropriate using meta-analysis if appropriate, or 
a narrative synthesis if meta-analysis is not appropriate. 
Search strategy - Embase 
Thrombocytosis OR platelet* (as a key word) OR thrombocyte OR thrombocyte count OR 
thrombocyte volume (MeSH terms) 
AND 
neoplasm OR carcinoma (mesh terms) OR cancer, carcinoma or paraneoplastic as key words 
AND* 
primary medical care OR primary health care OR general practice OR family medicine (mesh terms) 
Search strategy – Medline 
Thrombocytosis OR platelet* (as key words) OR blood platelets OR thrombocytosis OR platelet count 
(MeSH terms) 
AND 
neoplasms OR carcinoma (mesh terms) OR cancer as a key word 
AND* 
primary health care OR family practice OR general practice (mesh terms) OR primary care, family 
medicine, primary medical care as key words 
Search strategy – Web of Science & Cochrane Library 
Thrombocytosis OR platelet* OR thrombocyte  
AND 
neoplasm OR carcinoma OR cancer 
AND* 
primary medical care OR primary health care OR general practice OR family medicine  
*the search will be run with and without this final filter in the preliminary stages to see how the filter 
affects the results.  
 Endnote labels 
1=include 
2=exclude – not cancer 
3=exclude – not investigating association with thrombocytosis 
4=exclude – not primary care 
5=exclude – not >40y 
6=exclude – case study 
7=exclude - RCT 
 
Contributions 
Study design: SB. Search strategy and execution: SB. Title and abstract screening: SB and EA. Data 
extraction: SB and WH. Data interpretation and analysis: all authors.  
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